Ireland - English - HPRA (Health Products Regulatory Authority)

helm ag - exemestane - coated tablets - 25 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - exemestane - coated tablets - 25 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

creative pharma solutions s.r.o. - exemestane - film coated tablet - 25 milligram

Malta - English - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - exemestane - film-coated tablet - exemestane 25 mg - endocrine therapy

Malta - English - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - exemestane - film-coated tablet - exemestane 25 mg - endocrine therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - exemestane -

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; hypromellose; mannitol; microcrystalline cellulose; magnesium stearate; crospovidone; polysorbate 80; titanium dioxide; macrogol 400 - exemestane is indicated for the sequential adjuvant treatment of oestrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy. . exemestane is indicated for the treatment of oestrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; hypromellose; mannitol; microcrystalline cellulose; magnesium stearate; crospovidone; polysorbate 80; titanium dioxide; macrogol 400 - exemestane is indicated for the sequential adjuvant treatment of oestrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy. . exemestane is indicated for the treatment of oestrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - exemestane -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - exemestane -